Zoetis today announced the acquisition of Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with multiple locations across the UK and Ireland.
Zoetis Acquires Veterinary Pathology Group To Strengthen Veterinary Diagnostics In UK And Ireland
3 weeks ago 
363 views
Enhancing diagnostic capabilities to support better animal health outcomes
LEATHERHEAD,UK – Nov.11, 2025 – Zoetis Inc. today announced the acquisition of Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with multiple locations across the UK and Ireland. The acquisition further expands Zoetis’ comprehensive diagnostics portfolio and reinforces its commitment to advancing animal health through innovative, high-quality diagnostic solutions.
VPG’s extensive suite of multi-specialty diagnostic services and experienced team complement Zoetis’ existing capabilities, enabling enhanced support for veterinarians with faster, more accurate diagnostic insights that improve clinical outcomes for animals.
“Expanding our veterinary diagnostics footprint in the UK and Ireland through this acquisition is a key milestone in our strategy to provide innovative, best-in-class solutions to veterinary professionals,” said Abhay Nayak, President, Global Diagnostics at Zoetis. “VPG’s expertise and advanced laboratories support our vision to empower veterinarians and improve animal health and wellbeing. We are excited to welcome the VPG team to Zoetis and look forward to delivering long-term value together.”
“VPG’s national reputation for quality and deep expertise strengthens our ability to innovate and expand our diagnostic offerings to better serve the veterinary community in the UK and Ireland,” said Mike Ellinger, Business Unit Director, UK Diagnostics at Zoetis. “Our shared commitment to service excellence means we can continue to support veterinary customers seamlessly from day one. This acquisition strengthens our ability to innovate and expand our diagnostic offerings to better serve the veterinary community’s point-of-care and reference lab needs in the UK and Ireland.”
“This acquisition marks an exciting next step in VPG’s journey and a natural continuation of our evolution,” said Fiona Gosling, Chief Executive Officer at VPG. “Our customers can continue to expect the same high-quality, expert service they rely on from VPG, now further enhanced by the additional resources that Zoetis brings. Having long respected and admired Zoetis’ leadership in diagnostic innovation, we are delighted to bring together the remarkable talent within VPG with their scale and vision, underpinned by our shared values.”
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.
More from Zoetis
- Zoetis Hosts Free Webinar to Share Latest Knowledge of Lungworm
- Vets Urge Action as Dog Arthritis Misconceptions Persist
- Zoetis to Unveil End-to-End Support for Veterinary Care at London Vet Show 2025
- Vets asked to circulate clostridial disease survey to their farming clients
- Zoetis announced as principal sponsor of the newly titled Animal Medicines Amnesty
